
Thursday, March 07, 2024 12:10:00 AM
DCVax’s mechanism of action leverages the immune system and therefore is intuitive to doctors
A. All antigens, information
- DCVax uses actual tumor lysate and importantly presents hundreds of DIFFERENT tumor antigens to the immune system
- Other drugs don’t
B. Efficacy, holistic approach
- Diversity in weapons: T cells, B cells, and antibodies
- Diversity in targets: activates unique cytotoxic T cells, helper T cells, B cells, and antibodies to target each different tumor antigen
- Robust immune memory: after killing the cancer, some T cells and B cells will become immune memory cells and remain
- Other drugs don’t
C. Naturally is not toxic
- Immature T cells and B cells travel thru the thymus and spleen. This process naturally screens out and destroys the self-reactive (autoimmune, toxicity) immune cells.
- Other drugs don't
D. Renaissance in how cancer is treated
- Today doctors have a “drug” that does not cure and must balance efficacy against toxicity
- Tomorrow doctors will have a DCVax “vaccine”, so their focus can then include optimizing a total therapy, including quality of life
The prospect of cancer cure is what all cancer patients desire most
A. DCVax as a vaccine
- Creating a more robust immune memory equates to cure and prevention
- Highly efficacious, non-toxic profile
- Other drugs are not
B. DCVax may possibly vaccinate against Second Primary Cancers
- 19% of cancer patients get a second cancer sometime in their life (unrelated to their first cancer). https://pubmed.ncbi.nlm.nih.gov/24857148/
- Dr. Bosch made this interesting point. Many of the tumor antigens found on the GBM tumor lysate were also the same tumor antigens found in other cancers
- Hypothesis is a DCVax enhanced immune memory can protect against other cancers, especially for those with genetic or family predisposition to a certain cancer.
- Other drugs don't

Recent NWBO News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
- Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments • AllPennyStocks.com • 01/13/2025 01:56:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/26/2024 10:07:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 09:29:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 09:10:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:24:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
VAYK to Acquire Up to $9 million in Time-share Vacation Properties Through Non-Cash Deals • VAYK • Jun 11, 2025 9:45 AM
ECGI Holdings Invests in AI-Powered Fantasy Sports Startup Payday Fantasy • ECGI • Jun 10, 2025 8:30 AM
Avant Technologies Signs Letter of Intent for a Business Combination • AVAI • Jun 10, 2025 8:00 AM
NEXT10, Inc. Announces Acquisition of Torreon Group, Inc. • NXTN • Jun 9, 2025 8:42 AM
Maybacks Global Entertainment, LLC and Plex Sign Global Licensing and Distribution Agreement • AHRO • Jun 6, 2025 8:30 AM
Omega Laboratories Delivers Marijuana Breath Test Validation Packet to Cannabix Technologies Inc. - Completing Major Milestone under Strategic Partnership • BLOZF • Jun 5, 2025 8:54 AM